Qualigen Therapeutics, Inc.
  • About Us
    • Our Company
    • Leadership
    • Why We Do It
    • Board of Directors
    • Careers at Qualigen
    • Contact Us
  • Therapeutics
    • Pipeline
    • AS1411
    • ALAN
    • ALAN-RE
    • ALAN-CE
    • RAS-F
    • STARS
    • Resource Literature
      • AS1411 Resource Literature
      • RAS Resource Literature
  • Diagnostics
    • FastPack® IP
  • Patients
    • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Customer Support
    • Ordering
    • Technical Support
    • SDS
    • OnQ Training

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Mar 18, 2021 8:30am EDT

Qualigen Therapeutics, Inc. to present at the Benzinga Biotech Small Cap Conference

Mar 09, 2021 8:30am EST

Qualigen Therapeutics, Inc. Promotes Shishir Sinha to Chief Operating Officer Position

Mar 08, 2021 8:30am EST

Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference

Mar 01, 2021 8:30am EST

Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL

Jan 26, 2021 9:00am EST

Qualigen Therapeutics Announces Completion of Milestone Related to the License and Technology Transfer of its FastPack® Diagnostics Products in China

Jan 05, 2021 9:00am EST

Qualigen Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference

Dec 22, 2020 9:00am EST

Qualigen Therapeutics Issues CEO Letter to Stockholders with 2021 Outlook

Dec 18, 2020 3:07pm EST

Qualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct Offering

Dec 16, 2020 10:25am EST

Qualigen Therapeutics, Inc. Announces $12 Million Registered Direct Offering

Dec 15, 2020 9:00am EST

Qualigen Therapeutics Announces Issuance of U.S. Patent for Expanded Applications of ALAN Anticancer Platform Technology

  • 1
  • 2
  • 3
  • 4
  • 5
  • Next
RSS
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed

Qualigen Therapeutics, Inc. (Nasdaq: QLGN)
2042 Corte del Nogal

Suite B

Carlsbad, CA 92011

©2021 Qualigen
  • About Us
    ▼
    • Our Company
    • Leadership
    • Board of Directors
    • Careers at Qualigen
    • Contact Us
  • Therapeutics
    ▼
    • Pipeline
    • AS1411
    • ALAN
    • ALAN-RE
    • ALAN-CE
    • RAS-F
    • STARS
    • Resource Literature
      ▼
      • AS1411 Resource Literature
      • RAS Resource Literature
  • Diagnostics
    ▼
    • FastPack® IP
  • Patients
    ▼
    • Clinical Trials
  • Investors
    ▼
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Customer Support
    ▼
    • Ordering
    • Technical Support
    • SDS
    • OnQ Training